Ying-hong C. Shi
Zhongshan, China
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 120 publications
Liver resection after atezolizumab and bevacizumab versus maintenance therapy for locally advanced hepatocellular carcinoma (TALENTOP): a multicentre, open-label, randomised, phase 3 trial.
Journal: Lancet (London, England)
Published: April 29, 2026
Neoadjuvant GOLP in Resectable High-Risk Intrahepatic Cholangiocarcinoma.
Journal: The New England journal of medicine
Published: March 04, 2026
Y-STR allele deletion associated with Y-chromosome AZFabc subregion deletion: A case report
Journal: Fa yi xue za zhi
Published: December 23, 2025
Erratum: A positive feedback loop between cancer stem-like cells and tumor-associated neutrophils controls hepatocellular carcinoma progression.
Journal: Hepatology (Baltimore, Md.)
Published: August 14, 2025
Autophagy-promoted immunogenic cell death elicited by tyrosine kinase inhibitor orchestrates a synergistic immunotherapeutic microenvironment in hepatocellular carcinoma.
Journal: Experimental hematology & oncology
Published: July 23, 2025
Application of targeted deep sequencing for management of hepatocellular carcinoma in a real-world setting: prediction of MRD and adjuvant lenvatinib response.
Journal: Cancer letters
Published: July 16, 2025
Targeting HMGB2 acts as dual immunomodulator by bolstering CD8+ T cell function and inhibiting tumor growth in hepatocellular carcinoma.
Journal: Science advances
Published: May 02, 2025
Erratum: Mitogen-activated protein kinase kinase kinase 4 deficiency in intrahepatic cholangiocarcinoma leads to invasive growth and epithelial-mesenchymal transition.
Journal: Hepatology (Baltimore, Md.)
Published: April 07, 2025
Correction: MicroRNA-29a induces loss of 5-hydroxymethylcytosine and promotes metastasis of hepatocellular carcinoma through a TET-SOCS1-MMP9 signaling axis.
Journal: Cell death & disease
Published: November 14, 2024
Lysine-specific demethylase 1 deletion reshapes tumour microenvironment to overcome acquired resistance to anti-programmed death 1 therapy in liver cancer.
Journal: Clinical and translational medicine
Published: October 13, 2024
Sintilimab plus bevacizumab followed by resection in intermediate-stage hepatocellular carcinoma: a phase Ib clinical trial with biomarker analysis.
Journal: BMJ oncology
Published: August 26, 2024
Last Updated: 09/26/2026